Diagnostic Potential of the Salivary Biomarkers to Differentiate Statuses of Periodontitis
Diagnostic Potential of the Salivary (miRNAs - 146-a, 186, IL-1ß, and IL- 10) to Differentiate Statuses of Periodontitis: A Case-Control Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Baghdad, Iraq
- University of Baghdad
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female systemically healthy patients.
- Body mass index ≤ 30.
- Have a minimum of 20 teeth with facial and lingual scorable surfaces.
- Clinical criteria for periodontal health and periodontitis will be as follows :
1. Healthy periodontium (Group A): BOP <10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).
2. Periodontitis groups are defined as : i. Interdental CAL is detectable at ≥2 non-adjacent teeth, or ii. Buccal or oral CAL ≥3 mm with pocketing >3mm is detectable at ≥2teeth
Exclusion Criteria:
- Patients who refused to participate in the study.
- Individuals with dental implants.
- Previous history of extensive periodontal therapy preceding 6 months or currently under active periodontal treatment.
- Patients receiving antibiotic treatment or immunosuppressant medication within the last 3 months
- Pregnant or lactating mothers.
- Any symptoms of recent acute illness, e.g., COVID-19.
- Tobacco use.
Active orthodontic therapy
-
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
(Group A) periodontally healthy as a control
BOP <10%, PPD ≤ 3mm, intact periodontium (no probing attachment loss).
|
|
(Group B) periodontitis currently unstable
Generalized periodontitis, currently unstable (PPD ≥ 5mm or PPD at ≥ 4mm with BOP).
|
|
(Group C)periodontitis currently stable .
Generalized periodontitis, currently stable (BOP < 10 % PPD ≤4 mm and no BOP at 4mm sites)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diagnosis
Time Frame: base line
|
The primary outcomes will be determining salivary levels of (miRNAs 146-a, 186, IL-1β, and IL-10
|
base line
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: zainab J Raheem, MSc, University of Baghdad
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 527622
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.